Prostate cancer markers: An update (Review)

  • Authors:
    • Srinivas Pentyala
    • Terry Whyard
    • Sahana Pentyala
    • John Muller
    • John Pfail
    • Sunjit Parmar
    • Carlos G. Helguero
    • Sardar Khan
  • View Affiliations

  • Published online on: January 29, 2016     https://doi.org/10.3892/br.2016.586
  • Pages: 263-268
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

As the most common noncutaneous malignancy in American men, prostate cancer currently accounts for 29% of all diagnosed cancers, and ranks second as the cause of cancer fatality in American men. Prostatic cancer is rarely symptomatic early in its course and therefore disease presentation often implies local extension or even metastatic disease. Thus, it is extremely critical to detect and diagnose prostate cancer in its earliest stages, often prior to the presentation of symptoms. Three of the most common techniques used to detect prostate cancer are the digital rectal exam, the transrectal ultrasound, and the use of biomarkers. This review presents an update regarding the field of prostate cancer biomarkers and comments on future biomarkers. Although there is not a lack of research in the field of prostate cancer biomarkers, the discovery of a novel biomarker that may have the advantage of being more specific and effective warrants future scientific inquiry.

References

1 

Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin. 51:15–36. 2001. View Article : Google Scholar : PubMed/NCBI

2 

American Cancer Society Report. Cancer Facts and Figures. 2015.simplehttp://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015Accessed. November 08–2015

3 

Greenberg R: Does prostate cancer represent more than one cancer? Prostate Cancer: Science and Clinical Practice. Mydlo JH and Godec CJ: (San Diego, CA). Academic Press. 29–34. 2003. View Article : Google Scholar

4 

Gohiji K and Kitazawa S: Molecular mechanism of prostate cancer invasion and metastasis. Prostate Cancer: Science and Clinical Practice. Mydlo JH and Godec CJ: (San Diego, CA). Academic Press. 11–27. 2003. View Article : Google Scholar

5 

Gutman AB and Gutman EB: ‘Acid’ phosphatase occurring in serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest. 17:473–478. 1938. View Article : Google Scholar : PubMed/NCBI

6 

Heller JE: Prostatic acid phosphatase: Its current clinical status. J Urol. 137:1091–1103. 1987.PubMed/NCBI

7 

Bahnson RR and Catalona WJ: Adverse implications of acid phosphatase levels in the upper range of normal. J Urol. 137:427–430. 1987.PubMed/NCBI

8 

Lowe FC and Trauzzi SJ: Prostatic acid phosphatase in 1993. Its limited clinical utility. Urol Clin North Am. 20:589–595. 1993.PubMed/NCBI

9 

Burnett AL, Chan DW, Brendler CB and Walsh PC: The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. J Urol. 148:1832–1834. 1992.PubMed/NCBI

10 

Ablin RJ, Soanes WA, Bronson P and Witebsky E: Precipitating antigens of the normal human prostate. J Reprod Fertil. 22:573–574. 1970. View Article : Google Scholar : PubMed/NCBI

11 

Wang MC, Valenzuela LA, Murphy GP and Chu TM: Purification of a human prostate specific antigen. Invest Urol. 17:159–163. 1979.PubMed/NCBI

12 

Papsidero LD, Wang MC, Valenzuela LA, Murphy GP and Chu TM: A prostate antigen in sera of prostatic cancer patients. Cancer Res. 40:2428–2432. 1980.PubMed/NCBI

13 

Robert M, Gibbs BF, Jacobson E and Gagnon C: Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry. 36:3811–3819. 1997. View Article : Google Scholar : PubMed/NCBI

14 

Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:909–916. 1987. View Article : Google Scholar : PubMed/NCBI

15 

Tchetgen MB and Oesterling JE: The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia. Urol Clin North Am. 22:333–344. 1995.PubMed/NCBI

16 

Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL and Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol. 147:841–845. 1992.PubMed/NCBI

17 

Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM and Ross CA: Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology. 46:863–869. 1993.

18 

Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA and Mostofi FK: The Investigators of the American Cancer Society-National Prostate Cancer Detection Project: Characteristics of prostate cancers detected in a multimodality early detection program. Cancer. 72:1701–1708. 1993. View Article : Google Scholar : PubMed/NCBI

19 

Catalona WJ, Smith DS, Ratliff TL and Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 270:948–954. 1993. View Article : Google Scholar : PubMed/NCBI

20 

Babaian RJ and Camps JL: The role of prostate-specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy. Cancer. 68:2060–2063. 1991. View Article : Google Scholar : PubMed/NCBI

21 

Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr and Walsh PC: Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol. 138:92–98. 1987.PubMed/NCBI

22 

Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 277:1445–1451. 1997. View Article : Google Scholar : PubMed/NCBI

23 

Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, Montie JE, Pearson JD, Slezak JM and Zincke H: Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 164:1591–1595. 2000. View Article : Google Scholar : PubMed/NCBI

24 

Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI and Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 58:843–848. 2001. View Article : Google Scholar : PubMed/NCBI

25 

Ellis DW, Leffers S, Davies JS and Ng AB: Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. Am J Clin Pathol. 81:279–284. 1984.PubMed/NCBI

26 

Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP and Walsh PC: Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 143:747–752. 1990.PubMed/NCBI

27 

Stattin P, Vickers AJ, Sjoberg DD, Johansson R, Granfors T, Johansson M, Pettersson K, Scardino PT, Hallmans G and Lilja H: Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: A nested case-control study. Eur Urol. 68:207–213. 2015. View Article : Google Scholar : PubMed/NCBI

28 

Yousef GM and Diamandis EP: The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev. 22:184–204. 2001. View Article : Google Scholar : PubMed/NCBI

29 

Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1214–1220. 1995. View Article : Google Scholar : PubMed/NCBI

30 

Partin AW, Catalona WJ, Finlay JA, Darte C, Tindall DJ, Young CY, Klee GG, Chan DW, Rittenhouse HG, Wolfert RL, et al: Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis. Urology. 54:839–845. 1999. View Article : Google Scholar : PubMed/NCBI

31 

Haese A, Becker C, Noldus J, Graefen M, Huland E, Huland H and Lilja H: Human glandular kallikrein: 2 A potential serum marker for predicting the organ confined versus non organ confined growth of prostate cancer. J Urol. 163:1491–1497. 2000. View Article : Google Scholar : PubMed/NCBI

32 

Lee SW, Hosokawa K, Kim S, Jeong OC, Lilja H, Laurell T and Maeda M: Highly sensitive porpus silicon(P-Si)-based Human Kallikrein 2 (hK2) immunoassap platform toward accurate diagnosis of prostate cancer. Sens Basel. 15:11972–11987. 2015. View Article : Google Scholar

33 

Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 92:1472–1489. 2000. View Article : Google Scholar : PubMed/NCBI

34 

Djavan B, Bursa B, Seitz C, Soeregi G, Remzi M, Basharkhah A, Wolfram R and Marberger M: Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology. 54:603–606. 1999. View Article : Google Scholar : PubMed/NCBI

35 

Shariat SF, Bergamaschi F, Adler HL, Nguyen C, Kattan MW, Wheeler TM and Slawin KM: Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology. 56:423–429. 2000. View Article : Google Scholar : PubMed/NCBI

36 

Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM and Slawin KM: Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and −3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 20:833–841. 2002. View Article : Google Scholar : PubMed/NCBI

37 

Blobe GC, Schiemann WP and Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med. 342:1350–1358. 2000. View Article : Google Scholar : PubMed/NCBI

38 

Perry KT, Anthony CT and Steiner MS: Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. Prostate. 33:133–140. 1997. View Article : Google Scholar : PubMed/NCBI

39 

Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM and Slawin KM: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 19:2856–2864. 2001.PubMed/NCBI

40 

Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT and Thompson TC: Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 161:182–187. 1999. View Article : Google Scholar : PubMed/NCBI

41 

Perry KT, Anthony CT, Case T and Steiner MS: Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology. 49:151–155. 1997. View Article : Google Scholar : PubMed/NCBI

42 

Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM and Slawin KM: Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 10:1992–1999. 2004. View Article : Google Scholar : PubMed/NCBI

43 

Giri D, Ozen M and Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 159:2159–2165. 2001. View Article : Google Scholar : PubMed/NCBI

44 

Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM and Slawin KM: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 58:1008–1015. 2001. View Article : Google Scholar : PubMed/NCBI

45 

Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W, et al: Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol. 12:2634–2639. 1994.PubMed/NCBI

46 

Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM and Slawin KM: Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 62:5974–5979. 2002.PubMed/NCBI

47 

Gregorakis AK, Holmes EH and Murphy GP: Prostate-specific membrane antigen: Current and future utility. Semin Urol Oncol. 16:2–12. 1998.PubMed/NCBI

48 

Millon R, Jacqmin D, Muller D, Guillot J, Eber M and Abecassis J: Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: Clinical implications. Eur Urol. 36:278–285. 1999. View Article : Google Scholar : PubMed/NCBI

49 

Epstein JI, Carmichael M and Partin AW: OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology. 45:81–86. 1995. View Article : Google Scholar : PubMed/NCBI

50 

Shurbaji MS, Kalbfleisch JH and Thurmond TS: Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol. 27:917–921. 1996. View Article : Google Scholar : PubMed/NCBI

51 

Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W and Verhoeven G: Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 98:19–22. 2002. View Article : Google Scholar : PubMed/NCBI

52 

Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R and Getzenberg RH: Early identification of individuals with prostate cancer in negative biopsies. J Urol. 171:1419–1423. 2004. View Article : Google Scholar : PubMed/NCBI

53 

Bolduc S, Lacombe L, Naud A, Grégoire M, Fradet Y and Tremblay RR: Urinary PSA: A potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J. 1:377–381. 2007.PubMed/NCBI

54 

Woodson K, O'Reilly KJ, Hanson JC, Nelson D, Walk EL and Tangrea JA: The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol. 179:508–511; discussion 511–512. 2008. View Article : Google Scholar : PubMed/NCBI

55 

Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, Blase A, Koo S, Sarno M, Rittenhouse H, et al: A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta. 389:1–6. 2008. View Article : Google Scholar : PubMed/NCBI

56 

Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, et al: PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol. 179:1587–1592. 2008. View Article : Google Scholar : PubMed/NCBI

57 

Neves AF, Araújo TG, Biase WK, Meola J, Alcântara TM, Freitas DG and Goulart LR: Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem. 41:1191–1198. 2008. View Article : Google Scholar : PubMed/NCBI

58 

Tinzl M, Marberger M, Horvath S and Chypre C: DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol. 46:182–186; discussion 187. 2004. View Article : Google Scholar : PubMed/NCBI

59 

Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H and Babaian RJ: PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 179:1804–1810. 2008. View Article : Google Scholar : PubMed/NCBI

60 

van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, et al: The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 13:939–943. 2007. View Article : Google Scholar : PubMed/NCBI

61 

van Gils MP, Hessels D, van de Hulsbergen-Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG and Schalken JA: Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate. 68:1215–1222. 2008. View Article : Google Scholar : PubMed/NCBI

62 

Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB and Schalken JA: Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 13:5103–5108. 2007. View Article : Google Scholar : PubMed/NCBI

63 

Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, et al: A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68:645–649. 2008. View Article : Google Scholar : PubMed/NCBI

64 

Landers KA, Burger MJ, Tebay MA, Purdie DM, Scells B, Samaratunga H, Lavin MF and Gardiner RA: Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer. 114:950–956. 2005. View Article : Google Scholar : PubMed/NCBI

65 

Ronquist G and Nilsson BO: The Janus-faced nature of prostasomes. Their pluripotency favours the normal reproductive process and malignant prostate growth. Prostate Cancer Prostatic Dis. 7:21–31. 2004. View Article : Google Scholar : PubMed/NCBI

66 

Delves GH, Stewart AB, Cooper AJ and Lwaleed BA: Prostasomes, angiogenesis, and tissue factor. Semin Thromb Hemost. 33:75–79. 2007. View Article : Google Scholar : PubMed/NCBI

67 

Babiker AA, Hamad OA, Sanchez J, Ronquist G, Nilsson B and Ekdahl KN: Prothrombotic effect of prostasomes of metastatic cell and seminal origin. Prostate. 67:378–388. 2007. View Article : Google Scholar : PubMed/NCBI

68 

Chavarro JE, Stampfer MJ, Campos H, Kurth T, Willett WC and Ma J: A prospective study of trans-fatty acid levels in blood and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 17:95–101. 2008. View Article : Google Scholar : PubMed/NCBI

69 

Chavarro JE, Stampfer MJ, Li H, Campos H, Kurth T and Ma J: A prospective study of polyunsaturated fatty acid levels in blood and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 16:1364–1370. 2007. View Article : Google Scholar : PubMed/NCBI

70 

Gann PH, Hennekens CH, Ma J, Longcope C and Stampfer MJ: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 88:1118–1126. 1996. View Article : Google Scholar : PubMed/NCBI

71 

Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC and Giovannucci E: Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 14:1262–1269. 2005. View Article : Google Scholar : PubMed/NCBI

72 

Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P and Giles GG: Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 15:86–91. 2006. View Article : Google Scholar : PubMed/NCBI

73 

Prensner JR, Zhao S, Erho N, Schipper M, et al: RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 15:1469–1480. 2014. View Article : Google Scholar : PubMed/NCBI

74 

Øverbye A, Skotland T, Koehler CJ, Thiede B, Seierstad T, Berge V, Sandvig K and Llorente A: Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget. 6:30357–30376. 2015.PubMed/NCBI

Related Articles

Journal Cover

March 2016
Volume 4 Issue 3

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Pentyala, S., Whyard, T., Pentyala, S., Muller, J., Pfail, J., Parmar, S. ... Khan, S. (2016). Prostate cancer markers: An update (Review). Biomedical Reports, 4, 263-268. https://doi.org/10.3892/br.2016.586
MLA
Pentyala, S., Whyard, T., Pentyala, S., Muller, J., Pfail, J., Parmar, S., Helguero, C. G., Khan, S."Prostate cancer markers: An update (Review)". Biomedical Reports 4.3 (2016): 263-268.
Chicago
Pentyala, S., Whyard, T., Pentyala, S., Muller, J., Pfail, J., Parmar, S., Helguero, C. G., Khan, S."Prostate cancer markers: An update (Review)". Biomedical Reports 4, no. 3 (2016): 263-268. https://doi.org/10.3892/br.2016.586